Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA

Triple negative breast cancer is typically an aggressive and difficult to treat subtype. It is often associated with loss of function of the BRCA1 gene, either through mutation, loss of heterozygosity or methylation. This study aimed to measure methylation of the BRCA1 gene promoter at individual Cp...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2016-07, Vol.11 (7), p.e0160174-e0160174
Main Authors: Daniels, Sarah L, Burghel, George J, Chambers, Philip, Al-Baba, Shadi, Connley, Daniel D, Brock, Ian W, Cramp, Helen E, Dotsenko, Olena, Wilks, Octavia, Wyld, Lynda, Cross, Simon S, Cox, Angela
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biology and life sciences
Biomarkers, Tumor - blood
Biomarkers, Tumor - genetics
Blood
BRCA mutations
BRCA1 protein
BRCA1 Protein - genetics
Breast cancer
CpG Islands
Deoxyribonucleic acid
DNA
DNA Methylation
DNA, Neoplasm - blood
DNA, Neoplasm - genetics
Epigenetics
Female
Gene expression
Genetic aspects
Health risk assessment
Heterozygosity
Humans
Loss of heterozygosity
Medicine and Health Sciences
Methylation
Middle Aged
Mutation
Physiological aspects
Promoter Regions, Genetic
Research and Analysis Methods
Risk factors
Tissues
Triple Negative Breast Neoplasms - blood
Triple Negative Breast Neoplasms - genetics
Triple Negative Breast Neoplasms - pathology
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Triple negative breast cancer is typically an aggressive and difficult to treat subtype. It is often associated with loss of function of the BRCA1 gene, either through mutation, loss of heterozygosity or methylation. This study aimed to measure methylation of the BRCA1 gene promoter at individual CpG sites in blood, tumour and normal breast tissue, to assess whether levels were correlated between different tissues, and with triple negative receptor status, histopathological scoring for BRCA-like features and BRCA1 protein expression. Blood DNA methylation levels were significantly correlated with tumour methylation at 9 of 11 CpG sites examined (p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0160174